Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial.
高危急性心衰患者早期使用鈉葡萄糖共同轉運蛋白2抑製劑治療：EMPA-AHF試驗的理念和設計。
Am Heart J 2023-05-09
Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats.
Empagliflozin抑制線粒體活性氧自由基生成，減輕糖尿病大鼠對房顫的誘發性。
Front Cardiovasc Med 2023-02-24
Effects of empagliflozin on cardiac structure, function and biomarkers in patients with heart failure with preserved ejection fraction: study protocol for a randomised, placebo-controlled prospective trial.
Empagliflozin對心臟收縮功能保留型心衰患者心臟結構、功能和生物標記的影響：隨機、安慰劑對照前瞻性試驗的研究方案。
BMJ Open 2023-09-04
Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study.
該研究的標題翻譯為：「Dapagliflozin評估對隨後接受Cox-Maze IV手術的房顫患者的隨機試驗的理據和設計：DETAIL-CMIV研究」。
Europace 2024-01-15
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program.
針對心衰風險增加的老年肥胖患者使用 empagliflozin：Empire Prevent 試驗計畫的研究方案。
Am Heart J 2024-03-15
Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
Empagliflozin 抑制 HFpEF 患者心房心肌細胞中增加的鈉流入。
Cardiovasc Res 2024-05-10
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial.
冠狀動脈旁路移植術後 empagliflozin 預防心房纖維顫動效果的評估：雙盲、隨機、安慰劑對照試驗。
Naunyn Schmiedebergs Arch Pharmacol 2024-07-02
Empagliflozin protects the heart from atrial fibrillation in rats through inhibiting the NF-κB/HIF-1α regulatory axis and atrial remodeling.
Empagliflozin 透過抑制 NF-κB/HIF-1α 調控軸及心房重塑來保護大鼠心臟免受心房顫動的影響。
Int Immunopharmacol 2024-10-22